Mesothelioma

Researchers at Brigham and Women’s Hospital developed a tool that predicts risks for moderate to severe kidney injury after treatment with the chemotherapy drug cisplatin.

Between 1990 and 2019, global age-standardized incidence and mortality rates of mesothelioma went down, according to results published in Annals of the American Thoracic Society.

Compared with army and air force veterans in the U.K. and Australia, naval veterans more frequently had lung cancers linked to asbestos exposure, according to results published in Scientific Reports.

Healio spoke with Melina Elpi Marmarelis, MD, about key takeaways from the MARS 2 trial presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.

Healio spoke with Karen L. Reckamp, MD, professor in medicine and director of the division of medical oncology at Cedars-Sinai Medical Center, about key studies in lung cancer from ASCO Annual Meeting.

CHICAGO — The addition of pembrolizumab to chemotherapy significantly extended OS as first-line therapy for adults with advanced malignant pleural mesothelioma, according to results of the randomized phase 3 IND.227/KEYNOTE-483 trial.

Pembrolizumab demonstrated clinical activity among patients with diffuse malignant peritoneal mesothelioma, regardless of PD-L1 status or histology, according to data published in JAMA Network Open.

The FDA announced several regulatory actions the past few weeks.

Social determinants of health and lack of access to specialty cancer care led to survival disparities among patients with malignant pleural mesothelioma, results of a retrospective study showed.

The addition of pembrolizumab to chemotherapy significantly extended OS as first-line therapy for advanced malignant pleural mesothelioma, according to the agent’s manufacturer.